Advertisement

Journal of Gastroenterology

, Volume 47, Issue 2, pp 118–126 | Cite as

Long-term administration of PPI reduces treatment failures after esophageal variceal band ligation: a randomized, controlled trial

  • Hisashi HidakaEmail author
  • Takahide Nakazawa
  • Guoqin Wang
  • Shigehiro Kokubu
  • Tsutomu Minamino
  • Juichi Takada
  • Yoshiaki Tanaka
  • Yusuke Okuwaki
  • Masaaki Watanabe
  • Satoshi Tanabe
  • Akitaka Shibuya
  • Wasaburo Koizumi
Original Article—Alimentary Tract

Abstract

Background and purpose

Elective esophageal variceal ligation (EVL) is performed to decrease the risk of variceal hemorrhage. EVL is associated with adverse effects, including post-ligated bleeding, chest pain, and dysphagia. Proton pump inhibitors (PPIs) are the most potent pharmacological agents for inhibition of gastric acid secretion. However, the long-term effect of PPIs after EVL remains unclear. The aim of this study was to assess the efficacy of rabeprazole, a PPI, after variceal eradication by EVL.

Methods

We performed a randomized, controlled trial in Kitasato University East Hospital. The primary endpoint was treatment failure, defined as variceal hemorrhage or severe medical complications. Between July 2007 and September 2010, 43 patients were randomized into this study and followed up until September 2010.

Results

Twenty-one patients in the rabeprazole arm received 10 mg rabeprazole daily after EVL, and 22 patients in the control received no antisecretory treatment from the same stage. Baseline characteristics did not differ between the groups (median Child-Pugh score, 6; median age, 62 years; median follow-up, 18.7 months). The trial was stopped early after an interim analysis showed that the risk of bleeding and failure of rabeprazole treatment was lower than that of no antisecretory treatment with the log-rank test showing a significant difference between the groups (P = 0.007) and a hazard ratio of 0.098 [95% confidence interval, 0.012–0.79 (P = 0.029)].

Conclusions

Long-term administration of PPIs reduced the risk of treatment failure after EVL. Acid suppression therapy should also be considered as a treatment option after EVL.

Keywords

Portal hypertension Endoscopic variceal ligation Proton pump inhibitor Rabeprazole 

Abbreviations

EVL

Endoscopic variceal ligation

PPI

Proton pump inhibitor

HVPG

Hepatic venous pressure gradient

ARB

Angiotensin II type 1 receptor blocker

HCC

Hepatocellular carcinoma

ITT

Intention-to-treat

SD

Standard deviation

HR

Hazard ratio

Notes

Acknowledgments

The authors thank the radiologists of Kitasato University East Hospital for their technical assistance. We also thank Robert E. Brandt (Founder, CEO, and CME, MedEd, Japan) for editing the manuscript.

Conflict of interest

None.

References

  1. 1.
    North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med. 1988;319:983–9.Google Scholar
  2. 2.
    D’Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis. 1999;19:475–505.PubMedCrossRefGoogle Scholar
  3. 3.
    Garcia-Tsao G, Bosch J, Groszmann RJ. Portal hypertension and variceal bleeding–unresolved issues. Summary of an American Association for the study of liver diseases and European Association for the study of the liver single-topic conference. Hepatology. 2008;47:1764–72.PubMedCrossRefGoogle Scholar
  4. 4.
    Bolognesi M, Balducci G, Garcia-Tsao G, Gatta A, Gines P, Merli M, et al. Complications in the medical treatment of portal hypertension. Portal hypertension III. In: Proceedings of the third Baveno international consensus workshop on definitions, methodology and therapeutic strategies. Oxford: Blackwell Science; 2001. p. 180–203.Google Scholar
  5. 5.
    Khuroo MS, Khuroo NS, Farahat KL, Khuroo YS, Sofi AA, Dahab ST. Meta-analysis: endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleeding. Aliment Pharmacol Ther. 2005;21:347–61.PubMedCrossRefGoogle Scholar
  6. 6.
    Stiegman GV, Goff JS, Michaletz-Onody PA, Korula J, Lieberman D, Saeed ZA, et al. Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices. N Engl J Med. 1992;326:1527–32.CrossRefGoogle Scholar
  7. 7.
    Gimson AE, Ramage JK, Panos MZ, Hayllar K, Harrison PM, Williams R, et al. Randomized trial of variceal banding ligation versus injection sclerotherapy for bleeding oesophageal varices. Lancet. 1993;342:391–4.PubMedCrossRefGoogle Scholar
  8. 8.
    Cotton PB, Williams CB. Practical gastrointestinal endoscopy. Cambridge: Blackwell Science; 1996.Google Scholar
  9. 9.
    Shaheen NJ, Stuart E, Schmitz SM, Mitchell KL, Fried MW, Zacks S, et al. Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: a randomized, controlled trial. Hepatology. 2005;41:588–94.PubMedCrossRefGoogle Scholar
  10. 10.
    Tajiri T, Yoshida H, Obara K, Onji M, Kage M, Kitano S, et al. General rules for recording endoscopic findings of esophagogastric varices. 2nd ed. Dig Endosc. 2010;22:1–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Yoshida H, Mamada Y, Taniai N, Yamamoto K, Kawano Y, Mizuguchi Y, et al. A randomized control trial of bi-monthly versus bi-weekly endoscopic variceal ligation of esophageal varices. Am J Gastroenterol. 2005;100:2005–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Jutabha R, Jensen DM, Martin P, Savides T, Han SH, Gornbein J. Randomized study comparing banding and propranolol to prevent initial variceal hemorrhage in cirrhotics with high-risk esophageal varices. Gastroenterology. 2005;128:870–81.PubMedCrossRefGoogle Scholar
  13. 13.
    Bosch J, Mastai R, Kravetz D, Navasa M, Rodés J. Hemodynamic evaluation of the patient with portal hypertension. Semin Liver Dis. 1986;6:309–17.PubMedCrossRefGoogle Scholar
  14. 14.
    Sarin SK, Lamba GS, Kumar M, Misra A, Murthy NS. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. N Engl J Med. 1999;340:988–93.PubMedCrossRefGoogle Scholar
  15. 15.
    Bosch J, García-Pagán JC. Prevention of variceal rebleeding. Lancet. 2003;15(361):952–4.CrossRefGoogle Scholar
  16. 16.
    Schepke M, Kleber G, Nurnberg D, Willert J, Koch L, Veltzke-Schlieker W, et al. Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology. 2004;40:65–72.PubMedCrossRefGoogle Scholar
  17. 17.
    Thuluvath PJ, Maheshwari A, Jagannath S, Arepally A. A randomized controlled trial of beta-blockers versus endoscopic band ligation for primary prophylaxis: a large sample size is required to show a difference in bleeding rates. Dig Dis Sci. 2005;50:407–10.PubMedCrossRefGoogle Scholar
  18. 18.
    Norberto L, Polese L, Cillo U, Grigoletto F, Burroughs AK, Neri D, et al. A randomized study comparing ligation with propranolol for primary prophylaxis of variceal bleeding in candidates for liver transplantation. Liver Transpl. 2007;13:1272–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Young MF, Sanowski RA, Rasche R. Comparison and characterization of ulcerations induced by endoscopic ligation of esophageal varices versus endoscopic sclerotherapy. Gastrointest Endosc. 1993;39:119–22.PubMedCrossRefGoogle Scholar
  20. 20.
    Ahmed AM, al Karawi MA, Shariq S, Mohamed AE. Frequency of gastroesophageal reflux in patients with liver cirrhosis. Hepatogastroenterology. 1993;40:478–80.PubMedGoogle Scholar
  21. 21.
    Grande L, Planas R, Lacima G, Boix J, Ros E, Esteve M, et al. Sequential esophageal motility studies after endoscopic injection sclerotherapy: a prospective investigation. Am J Gastroenterol. 1991;86:36–40.PubMedGoogle Scholar
  22. 22.
    Sandy H, Kirsten MA. Esophageal acid-clearance and motility after endoscopic sclerotherapy of esophageal varices. Am J Gastroenterol. 1986;81:419–22.Google Scholar
  23. 23.
    Sauerbruch T, Wirsching R, Leisner B, Weinzierl M, Pfahler M, Paumgartner G. Esophageal function after sclerotherapy of bleeding varices. Scand J Gastroenterol. 1982;17:745–51.PubMedCrossRefGoogle Scholar
  24. 24.
    Hou MC, Yen TC, Lin HC, Kuo BI, Chen CH, Lee FY, et al. Sequential changes of esophageal motility after endoscopic injection sclerotherapy or variceal ligation for esophageal variceal bleeding: a scintigraphic study. Am J Gastroenterol. 1997;92:1875–8.PubMedGoogle Scholar
  25. 25.
    Spence RA, Smith JA, Isaacs S, Terblanche J. Disturbed oesophageal motility after eradication of varices by chronic sclerotherapy—a scintigraphic study. S Afr Med J. 1990;77:138–40.PubMedGoogle Scholar
  26. 26.
    Hoyumpa AM, Trevino-Alanis H, Grimes I, Humphries TJ. Rabeprazole: pharmacokinetics in patients with stable, compensated cirrhosis. Clin Ther. 1999;21:691–701.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2011

Authors and Affiliations

  • Hisashi Hidaka
    • 1
    Email author
  • Takahide Nakazawa
    • 1
  • Guoqin Wang
    • 2
  • Shigehiro Kokubu
    • 3
  • Tsutomu Minamino
    • 1
  • Juichi Takada
    • 1
  • Yoshiaki Tanaka
    • 1
  • Yusuke Okuwaki
    • 1
  • Masaaki Watanabe
    • 1
  • Satoshi Tanabe
    • 1
  • Akitaka Shibuya
    • 1
  • Wasaburo Koizumi
    • 1
  1. 1.Department of Gastroenterology, Internal MedicineKitasato University East HospitalSagamiharaJapan
  2. 2.Kitasato Clinical Research CenterKitasato University School of MedicineSagamiharaJapan
  3. 3.Department of GastroenterologyJuntendo University School of Medicine, Nerima HospitalTokyoJapan

Personalised recommendations